Volume 22 Supplement 1
Traumatic Brain Injury in 2020 – a horizon-scanning project
© Roberts et al; licensee BioMed Central Ltd. 2014
Published: 7 July 2014
Up to 62% of severe injuries in British patients include Traumatic Brain Injury (TBI) . 48% of these severe TBIs have unfavourable 6-month outcome with large variations in mortality and morbidity between centres . Most deaths occur from brainstem herniation . This project aimed to evaluate current best-practice for gaps in knowledge, care, and research, to determine what changes could best improve TBI care, and to project optimum treatment for 2020.
Post-graduate students constructed a current optimal patient pathway following brainstorming exercises. A comprehensive literature review of current and promising new treatments was performed. A new care pathway based on the direction of current research was predicted for 2020, which we believe could improve outcomes.
Best-practice TBI care is expensive and complex, requiring extensive infrastructure at all stages. Overall, there is weak evidence for much of TBI care. There are several reasons for this. TBI is often addressed as a single entity, rather than individual injury patterns with variable pathophysiology. Monitoring in the acute setting is difficult, with multiple options but no single modality with consistent evidence of benefit. Long-term outcome assessment is expensive with common tools providing little detailed information.
Large improvements in TBI care can be made by consistently and effectively applying treatments with known benefits. Funding is required to secure infrastructure required for optimal TBI care and evidence is required to secure this. A shift in thinking from ‘TBI’ to the assessment and treatment of individual injury patterns is important. Multimodal monitoring with computerised analysis of large registries shows promise in guiding treatment and research. Functional imaging and Patient-Reported Outcome Measurements can facilitate better evidence for aftercare. Research into tools such as novel biomarkers or drugs is important long-term, but a higher-quality evidence base is needed first as a foundation towards minimising gaps in care.
- National Confidential Enquiry into Perioperative Death: Trauma: Who Cares?. 2007, http://www.ncepod.org.uk/2007report2/Downloads/SIP_report.pdf (Last accessed October 20th 2013)Google Scholar
- Lingsma H, Roozenbeek B, Li B, Lu J, Weir J, Butcher I, et al: Large between-center differences in outcome after moderate and severe traumatic brain injury in the international mission on prognosis and clinical trial design in traumatic brain injury (IMPACT) study. Neurosurgery. 2011, 68: 601-608. 10.1227/NEU.0b013e318209333b.View ArticlePubMedGoogle Scholar
- Rusnak M, Janciak I, Majdan M, Wilbacher I, Mauritz W: Severe Traumatic Brain Injury in Austria VI: Effects of guideline-based management. Wien Klin Wochenschr. 2007, 119: 64-71. 10.1007/s00508-006-0765-0.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.